![]() | Only 14 pages are availabe for public view |
Abstract Nasal drug delivery is a promising approach for a rapid-onset delivery of medications and to circumvent their first-pass elimination when taken orally. Oxybutynin Chloride is a potent tertiary amine antimuscarinic agent, inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic receptors and blocking acetyl cholinergic activation. It is used for the management of urinary frequency. As its oral bioavailability is not exceeding 6%, the feasibility of developing an efficacious nasal formulation of oxybutynin has been investigated in this study. |